• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗机构中非重症艰难梭菌感染患者中甲硝唑和万古霉素使用情况的变化。

Changes in Metronidazole and Vancomycin Utilization for Nonsevere Clostridioides difficile Infection Among Institutions Caring for Children.

机构信息

From the Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center, Memphis, TN.

Department of Pharmacy, Le Bonheur Children's Hospital, Memphis, TN.

出版信息

Pediatr Infect Dis J. 2021 Jul 1;40(7):634-636. doi: 10.1097/INF.0000000000003117.

DOI:10.1097/INF.0000000000003117
PMID:33657601
Abstract

Clostridioides difficile infection guidelines were published in final format on April 1, 2018. Among 4962 and 3545 C. difficile infection cases in children the year before and after publication, oral metronidazole use decreased from 63.0% to 44.3% (P < 0.001) and oral vancomycin use increased from 27.3% to 47.7% (P < 0.001). Quarterly metronidazole utilization decreased postguidelines among 117 institutions, incidence rate ratios 0.86 (95% confidence intervals: 0.78-0.96).

摘要

艰难梭菌感染指南于 2018 年 4 月 1 日以最终形式发布。在发布前后的一年中,分别有 4962 例和 3545 例儿童艰难梭菌感染病例,口服甲硝唑的使用率从 63.0%降至 44.3%(P<0.001),口服万古霉素的使用率从 27.3%升至 47.7%(P<0.001)。在 117 家机构中,发布指南后每季度甲硝唑的使用率下降,发病率比值为 0.86(95%置信区间:0.78-0.96)。

相似文献

1
Changes in Metronidazole and Vancomycin Utilization for Nonsevere Clostridioides difficile Infection Among Institutions Caring for Children.医疗机构中非重症艰难梭菌感染患者中甲硝唑和万古霉素使用情况的变化。
Pediatr Infect Dis J. 2021 Jul 1;40(7):634-636. doi: 10.1097/INF.0000000000003117.
2
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.与最近的指南建议去除甲硝唑治疗非严重艰难梭菌感染相关的结果:一项回顾性、观察性、全国性队列研究。
Int J Antimicrob Agents. 2021 Mar;57(3):106282. doi: 10.1016/j.ijantimicag.2021.106282. Epub 2021 Jan 17.
3
Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.更新指南发布后,佐治亚州亚特兰大市社区获得性艰难梭菌感染治疗的变化,2018 年。
Anaerobe. 2021 Aug;70:102364. doi: 10.1016/j.anaerobe.2021.102364. Epub 2021 Apr 14.
4
Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.口服万古霉素治疗艰难梭菌感染与万古霉素耐药肠球菌风险。
Clin Infect Dis. 2020 Jul 27;71(3):645-651. doi: 10.1093/cid/ciz871.
5
Review of high dose vancomycin in the treatment of infection.高剂量万古霉素治疗感染的综述。
Infect Dis (Lond). 2020 Nov-Dec;52(12):847-857. doi: 10.1080/23744235.2020.1800080. Epub 2020 Aug 3.
6
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. fidaxomicin 与甲硝唑、万古霉素及其联合治疗首发、首次复发和严重艰难梭菌感染的疗效比较:一项观察性队列研究。
Int J Infect Dis. 2021 Feb;103:226-233. doi: 10.1016/j.ijid.2020.11.004. Epub 2020 Nov 11.
7
Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?静脉注射甲硝唑是否能改善艰难梭菌感染的疗效?
Clin Infect Dis. 2020 Dec 3;71(9):2414-2420. doi: 10.1093/cid/ciz1115.
8
Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.口服甲硝唑、万古霉素和非达霉素对艰难梭菌宿主脱落和环境污染的影响。
Clin Infect Dis. 2022 Mar 1;74(4):648-656. doi: 10.1093/cid/ciab473.
9
Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile-a German multicentre cohort study.万古霉素和甲硝唑对艰难梭菌初次感染后无事件生存的疗效比较:一项德国多中心队列研究。
Clin Microbiol Infect. 2024 Nov;30(11):1433-1438. doi: 10.1016/j.cmi.2024.08.003. Epub 2024 Aug 8.
10
Vancomycin Versus Metronidazole for Nonsevere Infection: Are the Data Adequate to Change Practice?万古霉素与甲硝唑治疗非重症感染:现有数据是否足以改变临床实践?
Ann Pharmacother. 2019 Aug;53(8):845-852. doi: 10.1177/1060028019829764. Epub 2019 Feb 8.

引用本文的文献

1
Clostridioides difficile Infections: Prevention and Treatment Strategies.艰难梭菌感染:预防与治疗策略。
Adv Exp Med Biol. 2024;1449:175-186. doi: 10.1007/978-3-031-58572-2_11.
2
Clostridium difficile infection in pediatric patients (Review).儿童艰难梭菌感染(综述)
Biomed Rep. 2023 Dec 8;20(2):18. doi: 10.3892/br.2023.1706. eCollection 2024 Feb.
3
Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy.儿童艰难梭菌感染:流行病学、诊断、治疗的最新进展。
Pediatrics. 2023 Sep 1;152(3). doi: 10.1542/peds.2023-062307.
4
Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.免疫功能低下儿童艰难梭菌感染的流行病学、诊断和治疗。
J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S46-S51. doi: 10.1093/jpids/piab078.